1. Home
  2. GCDT vs LNAI Comparison

GCDT vs LNAI Comparison

Compare GCDT & LNAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

GCDT

Green Circle Decarbonize Technology Limited Ordinary Shares

N/A

Current Price

$0.67

Market Cap

9.9M

Sector

Industrials

ML Signal

N/A

Logo Lunai Bioworks Inc.

LNAI

Lunai Bioworks Inc.

HOLD

Current Price

$3.89

Market Cap

11.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GCDT
LNAI
Founded
1992
N/A
Country
Hong Kong
United States
Employees
N/A
29
Industry
Industrial Machinery/Components
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
9.9M
11.8M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
GCDT
LNAI
Price
$0.67
$3.89
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
2.1M
740.9K
Earning Date
05-16-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.55
$0.15
52 Week High
$5.32
$5.02

Technical Indicators

Market Signals
Indicator
GCDT
LNAI
Relative Strength Index (RSI) 44.37 76.31
Support Level $0.65 $0.30
Resistance Level $1.47 N/A
Average True Range (ATR) 0.20 0.39
MACD 0.00 0.06
Stochastic Oscillator 12.69 55.96

Price Performance

Historical Comparison
GCDT
LNAI

About GCDT Green Circle Decarbonize Technology Limited Ordinary Shares

Green Circle Decarbonize Technology Ltd is a company which provides advanced energy saving solutions supported by proprietary phase change thermal energy storage materials and thermal engineering services. As an advocate of decarbonization, the Company designs, develops and provides customized energy saving solutions that bring considerable economic benefits to our clients and reduce carbon emissions for a sustainable future.

About LNAI Lunai Bioworks Inc.

Lunai Bioworks Inc is a biopharmaceutical company. Through its subsidiaries, it is mainly focused on developing allogeneic cell and gene therapies to promote stronger immune system responses, potentially for long-term or life-long cancer remission in some of the deadliest cancers. The group is engaged in the development of RENB-DC11 and RENB-DC20 (potential cell therapeutic vaccine candidates for different types of cancer); a proprietary AI platform that analyzes genetics to provide earlier and more accurate cancer diagnosis; and machine learning pipelines that harmonize and analyze complex, heterogeneous datasets to uncover clinically actionable insights. The group's reportable segments are: RENB, BioSymetrics, and RENC. Geographically, it operates in the United States and Netherlands.

Share on Social Networks: